A New Role for Lateral Flow in Cancer Diagnosis - Summary - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

A New Role for Lateral Flow in Cancer Diagnosis

  • November 19, 2026

  • 3 min

Share

Objective:

To develop and evaluate a quantitative lateral flow immunoassay for measuring plasma soluble AXL (sAXL) as a potential aid to pancreatic ductal adenocarcinoma (PDAC) diagnosis.

Approach:
  • Assay development: Researchers optimized a colorimetric strip using capture and detection antibodies and anti-biotin gold nanoparticles. They first assessed the immunoreagents in a sandwich ELISA.
  • Evaluation: The lateral flow assay was tested on plasma from 20 patients with PDAC and 20 healthy controls and compared with ELISA measurements.
Key Findings:
  • The sandwich ELISA showed a linear sAXL response and a reported detection limit of 0.16 ng/mL.
  • The lateral flow assay detected higher sAXL concentrations in the PDAC group and statistically differentiated patients from healthy controls.
Interpretation:

The study provides an early evaluation of a quantitative lateral flow format for plasma sAXL measurement; it does not establish the assay for routine diagnosis or screening.

Limitations:
  • The clinical cohort was small and included only patients with PDAC and healthy controls.
  • The assay was not evaluated against chronic pancreatitis, benign pancreatic disease, other cancers, or inflammatory conditions.
  • Sensitivity, specificity, clinical cutoffs, reference intervals, and performance across disease stages remain to be established in larger, independent, multicenter studies.
Conclusion:

The findings do not support replacing imaging, histopathology, cytology, or laboratory ELISA with this assay.

Sources:

Original Source(s)

Related Content